Clear Search

Showing 2 results for “Aringer M” published 2025.

October 2025

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update

Ann Rheum Dis 2025;0:1−16 Doi: 10.1016/j.ard.2025.09.007

The updated EULAR recommendations provide evidence- and expert-based consensus on the management of SLE with kidney involvement, adjusted for severity, and taking into consideration long-term efficacy, safety, cost, and local availability of drugs. Fanouriakis A et al. updated the 2019 EULAR/ ERA-EDTA recommendations for the management of SLE with kidney involvement, taking into consideration emerging evidence and recent developments in the field.

more…

September 2025

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

RMD Open 2025;11:e005742 Doi:10.1136/rmdopen-2025-005742

In this long-term extension of the Phase 2 SLEek study, Merrill et al. report that through an additional 56-weeks of treatment, upadacitinib as monotherapy or combined with elsubrutinib demonstrated sustained or improved efficacy in multiple endpoints in patients with moderately to severely active SLE.

more…